[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peritoneal-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peritoneal-neoplasms":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,94,132,162,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100609378","phase-3-a-three-part-phase-3-study-of-sofetabart-mipitecan-in-participants-with-platinum-resistant-part-a-and-platinum-sensitive-parts-b-and-c-ovarian-cancer-100609378",false,"NCT07213804","A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer","FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.","FRAmework-01","Inclusion Criteria:\n\nPart A, B, and C:\n\n* Have histologically confirmed high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer.\n* Have confirmed availability of tumor tissue block or slides\n* Have radiographic progression on or after most recent line of systemic anticancer therapy\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Have measurable disease per RECIST v1.1\n\nPart A:\n\n* Have platinum-resistant disease, defined as radiographic progression less than or equal to (≤)6 months of the last administration of platinum therapy.\n* Have previously received 1 to 3 prior lines of systemic cytotoxic therapy. Up to 4 lines of prior cytotoxic therapy is allowed if one of those lines is mirvetuximab soravtansine.\n* Have received prior bevacizumab treatment, unless documented contraindication or intolerance.\n* Have received treatment with a poly (ADP-ribose) polymerase inhibitor (PARPi) if known to have a somatic or germline breast cancer gene (BRCA) mutation, if clinically indicated, unless documented contraindication or intolerance.\n\nPart B and C:\n\n* Have relapsed after first-line platinum-based chemotherapy and have platinum-sensitive disease defined as radiographic progression greater than (\\>)6 months of their last administration of platinum therapy\n* Have previously received 1 to 2 prior lines of systemic cytotoxic chemotherapy\n\nPart B:\n\n\\- Have previously received a PARPi, per local product label, with progression on, or within 6 months of completion of PARPi treatment.\n\nPart C:\n\n\\- Have not previously received a PARPi treatment.\n\nExclusion Criteria:\n\nParts A, B and C:\n\n\\- Have received prior antibody-drug conjugate (ADC) with a topoisomerase inhibitor payload.\n\nPart A:\n\n* Have primary platinum-refractory disease, defined as radiographic progression ≤ 1 month since the last dose of first-line platinum-containing chemotherapy.\n\nPart B and C:\n\n\\- Have clinically significant proteinuria\n\nPart C:\n\n\\- Have a known pathogenic BRCA1\u002F2 gene alteration (somatic or germline).","ALL","18 Years",{"count":20,"type":21},1630,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with platinum-resistant cancer, meaning their disease progressed during or within six months of platinum-based chemotherapy. Parts B and C enroll participants with platinum-sensitive cancer, whose disease responded and remained controlled for at least six months after completing platinum treatment. The researchers want to find out if Sofe-M works better than the standard treatments that doctors use now and to better understand how safe it is. Each participant's time in the study will depend on how they respond to the treatment.",[27,28,29,30],"Ovarian Neoplasms","Fallopian Tube Neoplasms","Peritoneal Neoplasms","Neoplasm Metastasis",[32,33,34,35],"Folate Receptor Alpha","Antibody-drug Conjugate","Platinum-Resistant","Platinum-Sensitive","RECRUITING","2026-06-11",{"date":39,"type":40},"2026-06-15","ACTUAL",{"date":42,"type":40},"2025-10-22",{"date":44,"type":21},"2031-08",{"name":46,"class":47},"Eli Lilly and Company","INDUSTRY",261,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100585743","phase-2-relacorilant-in-combination-with-different-treatment-regimens-in-patients-with-gynecological-cancers-100585743","NCT06906341","Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers","An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)","Inclusion Criteria:\n\nArms A and B\n\n* Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma\n* Arm A Only: Platinum-resistant disease\n* Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor\n* Life expectancy of ≥3 months\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Able to swallow and retain oral medication\n* 1 to 3 lines of prior systemic anticancer therapy\n* Adequate organ function\n* Negative pregnancy test for patients of childbearing potential\n\nArm C\n\n* Stage III or IV, recurrent, or metastatic endometrial cancer\n* Life expectancy of ≥3 months\n* ECOG performance status of 0 or 1\n* Able to swallow and retain oral medication\n* Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD\\[L\\]1) antibody\n* 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer\n* Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections\n* Adequate organ function\n* Negative pregnancy test for patients of childbearing potential\n\nExclusion Criteria:\n\nArm A and B\n\n* Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel\n* Prior enrollment in a clinical trial of relacorilant\n* Prior anticancer therapy related toxicities not resolved to grade ≤1\n* Any surgery within 4 weeks prior to enrollment\n* Wide-field radiation to more than 25% of marrow-bearing areas\n* Medical conditions requiring chronic or frequent treatment with corticosteroids\n* Concurrent treatment with mifepristone or other glucocorticoid receptor modulators\n* Peripheral neuropathy from any cause \\>Grade 1\n* Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic\n* Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation\n* Bowel obstruction ≤12 weeks prior to study entry\n* Ascites or pleural effusions requiring therapeutic paracentesis\n* Untreated or symptomatic central nervous system metastases\n* History of other malignancy within 3 years prior to enrollment\n* Has received a live vaccine within 30 days prior to the study start date\n\nArm C\n\n* Has progressed while receiving weekly paclitaxel or nab-paclitaxel\n* Prior enrollment in a clinical trial of relacorilant\n* Prior anticancer therapy related toxicities not resolved to grade ≤1\n* Any surgery within 4 weeks prior to enrollment\n* Wide-field radiation to more than 25% of marrow-bearing areas\n* Medical conditions requiring chronic or frequent treatment with corticosteroids\n* Concurrent treatment with mifepristone or other glucocorticoid receptor modulators\n* Peripheral neuropathy from any cause \\>Grade 1\n* Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation\n* Bowel obstruction ≤12 weeks prior to study entry\n* Ascites or pleural effusions requiring therapeutic paracentesis\n* History of other malignancy within 3 years prior to enrollment\n* Has received a live vaccine within 30 days prior to the study start date\n* Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.","FEMALE",{"count":58,"type":21},270,[60],"PHASE2","This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.",[63,64,29,65],"Ovarian Cancer","Fallopian Tube Cancer","Endometrial Cancer",[67,68,69,70,71,28,27,29,72,73,74,75,76,77,78,79,80,81,82,83],"Genital Neoplasms, Female","Neoplasms by Site","Fallopian Tube Diseases","Ovarian Diseases","Neoplasms","Paclitaxel","Albumin-Bound Paclitaxel","Ovarian","Peritoneal or Advanced Fallopian Tube Cancer","High Grade","Platinum Resistant","Relacorilant","Bella","Nab-paclitaxel","Bevacizumab","Endometrial Neoplasm","Endometrial","2026-04-09",{"date":86,"type":40},"2026-04-14",{"date":88,"type":40},"2025-04-11",{"date":90,"type":21},"2026-12",{"name":92,"class":47},"Corcept Therapeutics",49,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":107,"conditions":108,"keywords":113,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":131},"100543100","efficacy-of-intraoperative-use-of-20-albumin-combined-with-ringer-lactate-versus-ringer-lactate-during-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy-100543100","NCT06351475","Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy","Evaluation de l'efficacité du Remplissage Vasculaire Par de l'ALBUmine Humaine 20% + Ringer Lactate comparé au Ringer Lactate Seul Chez Les Patients opérés Par cytoréduction Avec CHimiothérapie Intrapéritonéale hyPerthermique","ALBUCHIP","Inclusion Criteria:\n\n* Male and female patients aged 18 years old and older\n* Planned cytoreductive surgery with HIPEC for peritoneal carcinomatosis (from gynaecological or digestive origin)\n* Patient volunteer for the study and provided written informed consent\n* Patient affiliated to the French Health Insurance\n\nExclusion Criteria:\n\n* Adults \\>75 years old\n* Functional status rendering the patient ineligible for cytoreduction with CHIP (ECOG \\> 2 or Karnofsky index \\\u003C 75)\n* Pre-existing preoperative conditions affecting albuminemia (hepatic cirrhosis, nephrotic syndrome, exudative enteropathy, malnutrition)\n* Severe preoperative hypoalbuminemia (albuminemia \\\u003C 20 g\u002FL)\n* History of chronic left heart failure with reduced left ventricular ejection fraction (left ventricular ejection fraction \\\u003C 40%)\n* Patients at high risk of perioperative and postoperative pulmonary complications (atelectasis, significant pleural effusions)\n* Significant ascites with preoperative respiratory repercussions\n* Uncontrolled diabetes (HbA1c \\> 8.5%)\n* Allergy to exogenous human albumin and its excipients.\n* Contraindication to the administration of Ringer's lactate (history of allergy)\n* Hyperkalemia \\> 6.0 mmol\u002FL\n* Hypercalcemia (total calcium \\> 2.60 mmol\u002FL)\n* Chronic use of digitalis and hyperkalemic diuretics\n* Pregnancy, breastfeeding\n* Known preoperative renal failure (GFR \\\u003C 30 mL\u002Fmin\u002F1.73m2 or extrarenal purification)\n* Recent brain trauma \\\u003C 6 months (traumatic, ischemic, or hemorrhagic)\n* Participation in another interventional study involving human subjects or being in the exclusion period following a previous study involving human subjects, if applicable\n* Patient deprived of liberty\n* Patient under guardianship or curatorship","80 Years",{"count":104,"type":21},140,[106],"NA","Introduction Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is considered as the standard of care for the treatment of peritoneal metastases. Cytoreductive surgery with HIPEC is characterized by large intra operative fluid shift secondary to surgical resection, peritoneal inflammation and capillary shifts, requesting high volume of intra operative fluid therapy. Previous studies found a strong association between intra operative hypovolemia or volume overload with post operative outcomes. Albumin as an intravenous fluid has been widely studied in critical ill patients, but evaluation of its efficacy during major surgery on post operative clinical outcomes are lacking. We hypothesize that a reduction of intra operative crystalloid volume infusion by using 20% albumin during CRS with HIPEC could improve patients' prognosis. The aim of this study will be to assess the efficacy of 20% albumin combined with Ringer Lactate versus Ringer Lactate for fluid therapy during CRS with HIPEC on post operative outcome at 28 day.\n\nMethods and analysis The study protocol has been designed and written in accordance with the Prospective randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.\n\nRecruitment, randomisation and allocation Information on the study and screening of patients will be conducted during the consultation of anaesthesia (= selection visit), 2 months at 3 days before the surgery. Information notice and consent form will be delivered. The day before the surgery, anaesthesiologist who will conduct the pre anaesthetic visit will be able to include patients in the study (=inclusion visit). Randomisation will be done at the inclusion visit after information and signature of consent form of voluntary patients. A randomization number will be assigned. The 1:1 randomisation will be centralized via an online interface ensuring secret group assignment, and based on predefined randomisation lists with variable-size permutation blocks, stratified by center. Randomisation will be accomplished using a computer-generated random sequence.\n\nRandomized Open, Blinded endpoint (PROBE) design. This study is a randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.\n\nIntervention\n\n* 20% Albumin + Ringer Lactate group (intervention group) Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL\u002Fkg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g\u002FL). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.\n* Control group Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.\n\nOutcome measures The primary outcome will be the Comprehensive Complication Index (CCI score) at day 28 after CRS with HIPEC. Secondary outcomes are mortality at day 28, CCI score at day 7, volume of intra operative and post operative (48h) post operative fluid therapy, cumulated incidence of surgical post operative complications, cumulated incidence of medical post operative complications, need for mechanical ventilation, renal replacement therapy between surgery and day 28, SOFA score variation between pre operative period and 48h after surgery, number of days alive out of intensive care unit and out of hospital until day 28\n\nSample size calculation To ensure a power of 80%, a number of patients 130 (65 patients by group) will be necessary with a reduction of 13.6 (SD 24) points of the CCI score at day 28 in the intervention group. Because of a risk of neoplastic evolution between anaesthetic consultation and randomisation (10% of early cancellation), a total of 146 patients (73 by group) will be included in the study.\n\nDiscussion In summary, ALBUCHIP study will be the first randomized clinical trial assessing efficacy of intraoperative use of 20% albumin combined with Ringer Lactate versus Ringer Lactate during CRS with HIPEC. Results yielded from this study will be helpful for vascular filling during CRS with HIPEC but, thanks to ancillary studies, to improve pathophysiological understanding of this surgery.",[29,109,110,111,112],"Hyperthermic Intraperitoneal Chemotherapy","Intraoperative Care","Fluid Therapy","Postoperative Complications",[114,115,116,117,118,119,120],"Cytoreductive surgery","Hyperthermic intraperitoneal chemotherapy","Albumin administration","Fluid therapy","Post operative prognosis","Randomized clinical trial","Open label clinical trial","2025-11-28",{"date":123,"type":40},"2025-12-05",{"date":125,"type":40},"2025-09-03",{"date":127,"type":21},"2027-10",{"name":129,"class":130},"Assistance Publique - Hôpitaux de Paris","OTHER",7,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":56,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100613961","phase-1-tolerance-safety-efficacy-and-pharmacokinetics-of-pressurized-intraperitoneal-aerosol-chemotherapy-pipac-using-paclitaxel-for-platinum-resistant-recurrent-ovarian-cancer-100613961","NCT07273396","Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer","A Phase 1\u002F2a Study to Evaluate the Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer With Peritoneal Metastasis (PIPAC-OVPAC 1\u002F2a)","Inclusion Criteria:\n\n1. Age: Women aged 19-85 years.\n2. Diagnosis: Histologically confirmed ovarian, fallopian tube, or peritoneal cancer.\n3. Platinum Status:\n\n   * Refractory: Disease progression during platinum-based chemotherapy.\n   * Resistant: Progression within 6 months (24 weeks) post-platinum therapy.\n4. Prior Therapies: ≥2 prior intravenous chemotherapies (may include paclitaxel).\n5. Treatment Options: Unresponsive to\u002Fineligible for standard therapies (e.g., intolerance, hypersensitivity) and ineligible for surgical resection.\n6. Measurable Disease: ≥1 measurable\u002Fevaluable peritoneal lesion per RECIST 1.1.\n7. Metastasis: ≤1 asymptomatic distant metastasis (excluding retroperitoneal lymph nodes, pleural effusion, localized skin metastases).\n8. Imaging Confirmation: Peritoneal carcinomatosis confirmed by PET-CT\u002FCT.\n9. Performance Status: ECOG 0-2.\n10. Pregnancy\u002FContraception:\n\n    * Non-pregnant\u002Fnon-lactating.\n    * Contraception: Effective methods (IUD, sterilization) for 6 months post-PIPAC (childbearing potential only).\n11. Organ Function:\n\n    * Bone Marrow: ANC \\>1,500\u002Fmm³, platelets \\>100,000\u002Fmm³, hemoglobin \\>8.0 g\u002FdL.\n    * Liver: Bilirubin ≤1.5×ULN, AST\u002FALT ≤1.5×ULN.\n    * Kidney: Creatinine ≤1.5×ULN, creatinine clearance \\>60 mL\u002Fmin.\n    * Lungs: FVC\u002FFEV1 ≥70% predicted.\n    * Coagulation: INR ≤1.5, aPTT ≤1.5×ULN.\n12. Consent: Signed informed consent.\n\nExclusion Criteria:\n\n1. ≥2 distant metastases (excluding retroperitoneal lymph nodes, pleural effusion, and localized skin metastases).\n2. Contraindications to paclitaxel per approved domestic labeling.\n3. Hypersensitivity history to paclitaxel or PIPAC devices.\n4. Uncontrolled comorbidities per investigator judgment:\n\n   * NYHA Class ≥II heart failure\n   * Clinically significant cardiovascular disease (e.g., arrhythmia, myocardial infarction)\n   * Immunosuppressive conditions (AIDS, autoimmune diseases, immunosuppressive therapy)\n   * Active HBV\u002FHCV infection\n   * Uncontrolled hypertension (systolic \\>160 mmHg or diastolic \\>100 mmHg)\n   * Uncontrolled diabetes (HbA1c \\>8%)\n   * Radiographic\u002Fclinical bowel obstruction.\n5. IV chemotherapy within 4 weeks prior to Cycle 1 PIPAC.\n6. Life expectancy \\\u003C3 months.\n7. Prior PIPAC therapy.\n8. Medically unfit for general anesthesia or laparoscopic surgery.\n9. Refusal of contraception:\n\n   \\- Medically acceptable methods:\n   * Intrauterine device (failure rate \\\u003C1%)\n   * Surgical sterilization (tubal ligation, hysterectomy, vasectomy; failure rate \\\u003C0.5%).\n10. Participation in another clinical trial within 1 month of screening.\n11. Other exclusionary factors per investigator discretion.","19 Years","85 Years",{"count":142,"type":21},53,[144,60],"PHASE1","The purpose of this study is to evaluate the tolerance, safety, efficacy, and pharmacokinetics of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with paclitaxel in patients with platinum-resistant recurrent ovarian cancer and peritoneal carcinomatosis.",[27,29],[148,149,150,151],"Pressurized intraperitoneal aerosol chemotherapy","platinum-resistant recurrent","ovarian cancer","paclitaxel","NOT_YET_RECRUITING","2025-11-27",{"date":155,"type":40},"2025-12-09",{"date":157,"type":21},"2026-01-01",{"date":159,"type":21},"2030-08-31",{"name":161,"class":130},"Seoul National University Hospital",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":56,"minAge":18,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":179,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":142},"100371101","phase-3-maintenance-therapy-with-aromatase-inhibitor-in-epithelial-ovarian-cancer-matao-100371101","NCT04111978","MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)","MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54\u002FSwiss-GO-2\u002FMATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).","MATAO","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age\n* Willing and able to attend the visits and to understand all study-related procedures.\n* Primary, newly diagnosed FIGO Stage II to IV and histologically confirmed low or high grade serous or endometrioid epithelial ovarian\u002Ffallopian tube\u002Fperitoneal cancer\n* (Interval-) debulking performed ECOG-Performance Status 0-2\n* Signed informed consents (ICF-1; ICF-2)\n* Paraffin-embedded tissue or paraffin-embedded cell block (from ascites) available\n* Positivity (≥ 1%) for ER expression (only determined by Histopathology Core Facility of MATAO trial)\n* At least 4 cycles of platinum-based chemotherapy (neoadjuvant allowed)\n* Negative serum pregnancy test in women of childbearing potential who will get\u002Fhave gotten a surgical resection or radiation sterilization, prior to the intervention in the therapeutical maintenance setting.\n\nExclusion Criteria:\n\n* Progressive disease at the end of adjuvant treatment as defined in chapter 9.2.1 of protocol\n* Women of childbearing potential (not having undergone a surgical or radiation sterilization and not getting a surgical resection, prior to the intervention in the therapeutical maintenance setting)\n* Pregnant or lactating women\n* Any other malignancy within the last 5 years which has impact on the prognosis of the patient\n* \\\u003C 4 cycles of chemotherapy in total\n* Contraindications to endocrine therapy\n* Inability or unwillingness to swallow tablets\n* Patients with a known intolerance to galactose, lactase deficiency and glucose-galactose malabsorption",{"count":171,"type":21},540,[24],"The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo.\n\nThe study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).",[175,28,29,176,177,178],"Ovarian Neoplasm Epithelial","High-grade Serous Ovarian Carcinoma (HGSOC)","Low-grade Serous Ovarian Carcinoma (LGSOC)","Ovarian Endometrioid Carcinoma",[180,181,182,183],"maintenance therapy","aromatase inhibitor","primary ovarian cancer","estrogen-receptor","2025-09-23",{"date":186,"type":40},"2025-09-29",{"date":188,"type":40},"2020-11-05",{"date":190,"type":21},"2032-07-01",{"name":192,"class":193},"Swiss GO Trial Group","NETWORK",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":221},"100360735","development-of-a-cinical-and-biological-database-in-ovarian-fallopian-tube-and-peritoneal-cancers-100360735","NCT03976999","Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers","Development of a Prospective and Monocentric Cinical and Biological Database in Epithelial Ovarian Cancer, Fallopian Tube Cancer and Primitive Peritoneal Cancer","BCBOvaire","Inclusion Criteria:\n\n* 18 or older\n* Patient at the diagnosis of an epithelial ovarian cancer, or a fallopian tube caner or a primitive peritoneal cancer\n* Patient eligible for, at least, one surgery and a chemotherapy\n* Patient having given his informed, written and express consent\n\nExclusion Criteria:\n\n* Patient not affiliated to a social protection scheme\n* Pregnant and \u002F or nursing women\n* Subject under tutelage, curatorship or safeguard of justice\n* Patient whose regular follow-up is impossible for psychological, familial, social or geographical reasons",{"count":203,"type":21},300,[106],"A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical datas to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to epithetial ovarian cancer, Fallopian tube cancer and Primitive peritoneal cancer.",[207,28,29],"Carcinoma, Ovarian Epithelial",[209,210,211],"Biological Specimen Banks","Cancer","Gynecology","2025-02-11",{"date":214,"type":40},"2025-02-12",{"date":216,"type":40},"2017-07-05",{"date":218,"type":21},"2032-07",{"name":220,"class":130},"Institut du Cancer de Montpellier - Val d'Aurelle",1]